nodes	percent_of_prediction	percent_of_DWPC	metapath
Etodolac—osteoarthritis—Prednisone—psoriasis	0.357	1	CpDpCtD
Etodolac—RXRA—Acitretin—psoriasis	0.168	0.337	CbGbCtD
Etodolac—UGT1A10—Mycophenolate mofetil—psoriasis	0.103	0.207	CbGbCtD
Etodolac—UGT1A9—Mycophenolic acid—psoriasis	0.0464	0.0932	CbGbCtD
Etodolac—UGT2B7—Mycophenolic acid—psoriasis	0.0439	0.0882	CbGbCtD
Etodolac—UGT1A9—Mycophenolate mofetil—psoriasis	0.0259	0.0521	CbGbCtD
Etodolac—UGT2B7—Mycophenolate mofetil—psoriasis	0.0245	0.0493	CbGbCtD
Etodolac—ALB—Acitretin—psoriasis	0.0172	0.0345	CbGbCtD
Etodolac—PTGS2—Triamcinolone—psoriasis	0.0128	0.0256	CbGbCtD
Etodolac—PTGS2—Betamethasone—psoriasis	0.0109	0.022	CbGbCtD
Etodolac—ALB—Mycophenolate mofetil—psoriasis	0.00804	0.0162	CbGbCtD
Etodolac—SLC22A6—Cyclosporine—psoriasis	0.00716	0.0144	CbGbCtD
Etodolac—ALB—Prednisone—psoriasis	0.00643	0.0129	CbGbCtD
Etodolac—PTGS2—Dexamethasone—psoriasis	0.00636	0.0128	CbGbCtD
Etodolac—CYP2C9—Cholecalciferol—psoriasis	0.005	0.01	CbGbCtD
Etodolac—SLC22A6—Methotrexate—psoriasis	0.00379	0.00761	CbGbCtD
Etodolac—CYP2C9—Cyclosporine—psoriasis	0.00328	0.0066	CbGbCtD
Etodolac—ALB—Methotrexate—psoriasis	0.00323	0.00648	CbGbCtD
Etodolac—CYP2C9—Dexamethasone—psoriasis	0.00216	0.00434	CbGbCtD
Etodolac—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.000387	0.157	CbGdCrCtD
Etodolac—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.00031	0.126	CbGdCrCtD
Etodolac—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.000301	0.122	CbGdCrCtD
Etodolac—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.000234	0.0948	CbGdCrCtD
Etodolac—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000191	0.00794	CbGpPWpGaD
Etodolac—UGT1A9—Metapathway biotransformation—CYP2S1—psoriasis	0.000189	0.00787	CbGpPWpGaD
Etodolac—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000188	0.00784	CbGpPWpGaD
Etodolac—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000187	0.076	CbGdCrCtD
Etodolac—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000187	0.076	CbGdCrCtD
Etodolac—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000182	0.0738	CbGdCrCtD
Etodolac—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.00018	0.00751	CbGpPWpGaD
Etodolac—PTGS2—Overview of nanoparticle effects—CRP—psoriasis	0.000172	0.00718	CbGpPWpGaD
Etodolac—RXRA—Nuclear Receptor transcription pathway—VDR—psoriasis	0.00017	0.00706	CbGpPWpGaD
Etodolac—ALB—HDL-mediated lipid transport—APOE—psoriasis	0.000165	0.00686	CbGpPWpGaD
Etodolac—RXRA—Orphan transporters—CARM1—psoriasis	0.000161	0.00669	CbGpPWpGaD
Etodolac—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000156	0.00651	CbGpPWpGaD
Etodolac—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000156	0.0065	CbGpPWpGaD
Etodolac—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000155	0.00644	CbGpPWpGaD
Etodolac—UGT1A3—NRF2 pathway—TGFA—psoriasis	0.000155	0.00643	CbGpPWpGaD
Etodolac—RXRA—PPARA activates gene expression—CARM1—psoriasis	0.000154	0.0064	CbGpPWpGaD
Etodolac—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.00015	0.00626	CbGpPWpGaD
Etodolac—RXRA—Nuclear Receptors—PPARG—psoriasis	0.00015	0.00623	CbGpPWpGaD
Etodolac—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—psoriasis	0.000142	0.00592	CbGpPWpGaD
Etodolac—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000141	0.00588	CbGpPWpGaD
Etodolac—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.000141	0.0574	CbGdCrCtD
Etodolac—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.000141	0.0574	CbGdCrCtD
Etodolac—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000138	0.0561	CbGdCrCtD
Etodolac—UGT1A9—PPARA activates gene expression—CARM1—psoriasis	0.000134	0.00557	CbGpPWpGaD
Etodolac—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000133	0.00553	CbGpPWpGaD
Etodolac—UGT2B7—NRF2 pathway—TGFA—psoriasis	0.000131	0.00547	CbGpPWpGaD
Etodolac—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000131	0.00545	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000129	0.00535	CbGpPWpGaD
Etodolac—RXRA—Organelle biogenesis and maintenance—CARM1—psoriasis	0.000123	0.00513	CbGpPWpGaD
Etodolac—RXRA—Transcription factor regulation in adipogenesis—TNF—psoriasis	0.000123	0.00512	CbGpPWpGaD
Etodolac—RXRA—NRF2 pathway—TGFA—psoriasis	0.000123	0.0051	CbGpPWpGaD
Etodolac—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.00012	0.00498	CbGpPWpGaD
Etodolac—RXRA—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000118	0.00492	CbGpPWpGaD
Etodolac—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000115	0.00479	CbGpPWpGaD
Etodolac—UGT1A3—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000115	0.00478	CbGpPWpGaD
Etodolac—PTGS2—Overview of nanoparticle effects—CXCL8—psoriasis	0.000112	0.00467	CbGpPWpGaD
Etodolac—RXRA—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.000108	0.00448	CbGpPWpGaD
Etodolac—UGT1A9—NRF2 pathway—TGFA—psoriasis	0.000107	0.00444	CbGpPWpGaD
Etodolac—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000105	0.00435	CbGpPWpGaD
Etodolac—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000104	0.00431	CbGpPWpGaD
Etodolac—RXRA—Transcription factor regulation in adipogenesis—IL6—psoriasis	9.94e-05	0.00414	CbGpPWpGaD
Etodolac—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	9.84e-05	0.00409	CbGpPWpGaD
Etodolac—RXRA—Transcriptional regulation of white adipocyte differentiation—LEP—psoriasis	9.77e-05	0.00407	CbGpPWpGaD
Etodolac—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	9.65e-05	0.00401	CbGpPWpGaD
Etodolac—ALB—Lipoprotein metabolism—APOE—psoriasis	9.48e-05	0.00394	CbGpPWpGaD
Etodolac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	9.2e-05	0.00383	CbGpPWpGaD
Etodolac—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	9.19e-05	0.00382	CbGpPWpGaD
Etodolac—PTGS2—S1P1 pathway—VEGFA—psoriasis	9.11e-05	0.00379	CbGpPWpGaD
Etodolac—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	9.03e-05	0.00376	CbGpPWpGaD
Etodolac—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.77e-05	0.00365	CbGpPWpGaD
Etodolac—RXRA—Adipogenesis—SOCS1—psoriasis	8.71e-05	0.00362	CbGpPWpGaD
Etodolac—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	8.61e-05	0.00358	CbGpPWpGaD
Etodolac—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—psoriasis	8.6e-05	0.00358	CbGpPWpGaD
Etodolac—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	8.53e-05	0.0346	CbGdCrCtD
Etodolac—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	8.53e-05	0.0346	CbGdCrCtD
Etodolac—RXRA—Transcriptional regulation of white adipocyte differentiation—PPARG—psoriasis	8.51e-05	0.00354	CbGpPWpGaD
Etodolac—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	8.33e-05	0.0338	CbGdCrCtD
Etodolac—CYP2C9—Biological oxidations—CYP2S1—psoriasis	8.22e-05	0.00342	CbGpPWpGaD
Etodolac—RXRA—Regulation of Androgen receptor activity—JUN—psoriasis	8.14e-05	0.00339	CbGpPWpGaD
Etodolac—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	8.11e-05	0.00337	CbGpPWpGaD
Etodolac—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	8.03e-05	0.00334	CbGpPWpGaD
Etodolac—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	7.94e-05	0.0033	CbGpPWpGaD
Etodolac—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	7.94e-05	0.0033	CbGpPWpGaD
Etodolac—PTGS2—Overview of nanoparticle effects—TNF—psoriasis	7.81e-05	0.00325	CbGpPWpGaD
Etodolac—ALB—Hemostasis—SERPINB8—psoriasis	7.73e-05	0.00322	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—TARS—psoriasis	7.52e-05	0.00313	CbGpPWpGaD
Etodolac—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—psoriasis	7.44e-05	0.00309	CbGpPWpGaD
Etodolac—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	7.38e-05	0.00307	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	7.25e-05	0.00302	CbGpPWpGaD
Etodolac—SLC22A6—SLC-mediated transmembrane transport—CP—psoriasis	7.11e-05	0.00296	CbGpPWpGaD
Etodolac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—psoriasis	6.78e-05	0.00282	CbGpPWpGaD
Etodolac—ALB—Folate Metabolism—CAT—psoriasis	6.49e-05	0.0027	CbGpPWpGaD
Etodolac—RXRA—Adipogenesis—LEP—psoriasis	6.43e-05	0.00267	CbGpPWpGaD
Etodolac—RXRA—PPARA activates gene expression—PPARG—psoriasis	6.4e-05	0.00266	CbGpPWpGaD
Etodolac—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	6.4e-05	0.00266	CbGpPWpGaD
Etodolac—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	6.37e-05	0.00265	CbGpPWpGaD
Etodolac—PTGS2—Selenium Micronutrient Network—CAT—psoriasis	6.37e-05	0.00265	CbGpPWpGaD
Etodolac—ALB—Vitamin B12 Metabolism—CRP—psoriasis	6.33e-05	0.00263	CbGpPWpGaD
Etodolac—PTGS2—Overview of nanoparticle effects—IL6—psoriasis	6.3e-05	0.00262	CbGpPWpGaD
Etodolac—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	6.3e-05	0.00262	CbGpPWpGaD
Etodolac—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	6.26e-05	0.00261	CbGpPWpGaD
Etodolac—ALB—Vitamin B12 Metabolism—APOE—psoriasis	6.2e-05	0.00258	CbGpPWpGaD
Etodolac—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.11e-05	0.00254	CbGpPWpGaD
Etodolac—ALB—Folate Metabolism—IL4—psoriasis	5.96e-05	0.00248	CbGpPWpGaD
Etodolac—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	5.95e-05	0.00247	CbGpPWpGaD
Etodolac—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	5.86e-05	0.00244	CbGpPWpGaD
Etodolac—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	5.82e-05	0.00242	CbGpPWpGaD
Etodolac—RXRA—Transcriptional regulation of white adipocyte differentiation—NFKB1—psoriasis	5.81e-05	0.00242	CbGpPWpGaD
Etodolac—RXRA—Adipogenesis—PPARG—psoriasis	5.6e-05	0.00233	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—NDUFA5—psoriasis	5.58e-05	0.00232	CbGpPWpGaD
Etodolac—UGT1A9—PPARA activates gene expression—PPARG—psoriasis	5.58e-05	0.00232	CbGpPWpGaD
Etodolac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	5.56e-05	0.00231	CbGpPWpGaD
Etodolac—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	5.46e-05	0.00227	CbGpPWpGaD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	5.24e-05	0.00218	CbGpPWpGaD
Etodolac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	5.17e-05	0.00215	CbGpPWpGaD
Etodolac—ALB—Selenium Micronutrient Network—CAT—psoriasis	5.16e-05	0.00215	CbGpPWpGaD
Etodolac—ALB—Folate Metabolism—CRP—psoriasis	5.15e-05	0.00214	CbGpPWpGaD
Etodolac—PTGS2—Selenium Micronutrient Network—CRP—psoriasis	5.06e-05	0.00211	CbGpPWpGaD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.95e-05	0.00206	CbGpPWpGaD
Etodolac—RXRA—Generic Transcription Pathway—CARM1—psoriasis	4.91e-05	0.00204	CbGpPWpGaD
Etodolac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	4.81e-05	0.002	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—CYP2S1—psoriasis	4.75e-05	0.00197	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—NDUFA5—psoriasis	4.75e-05	0.00197	CbGpPWpGaD
Etodolac—ALB—Folate Metabolism—ICAM1—psoriasis	4.74e-05	0.00197	CbGpPWpGaD
Etodolac—PTGS2—Selenium Micronutrient Network—ICAM1—psoriasis	4.65e-05	0.00193	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—IL4—psoriasis	4.63e-05	0.00193	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—CARM1—psoriasis	4.62e-05	0.00192	CbGpPWpGaD
Etodolac—Tachycardia—Triamcinolone—psoriasis	4.6e-05	0.000389	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Hydrocortisone—psoriasis	4.56e-05	0.000386	CcSEcCtD
Etodolac—Hyperhidrosis—Triamcinolone—psoriasis	4.55e-05	0.000386	CcSEcCtD
Etodolac—Agranulocytosis—Methotrexate—psoriasis	4.55e-05	0.000385	CcSEcCtD
Etodolac—Convulsion—Dexamethasone—psoriasis	4.54e-05	0.000384	CcSEcCtD
Etodolac—Convulsion—Betamethasone—psoriasis	4.54e-05	0.000384	CcSEcCtD
Etodolac—Feeling abnormal—Mycophenolate mofetil—psoriasis	4.53e-05	0.000383	CcSEcCtD
Etodolac—Insomnia—Hydrocortisone—psoriasis	4.52e-05	0.000383	CcSEcCtD
Etodolac—RXRA—Transcriptional regulation of white adipocyte differentiation—TNF—psoriasis	4.52e-05	0.00188	CbGpPWpGaD
Etodolac—Hypertension—Dexamethasone—psoriasis	4.52e-05	0.000383	CcSEcCtD
Etodolac—Hypertension—Betamethasone—psoriasis	4.52e-05	0.000383	CcSEcCtD
Etodolac—Paraesthesia—Hydrocortisone—psoriasis	4.49e-05	0.00038	CcSEcCtD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.49e-05	0.00187	CbGpPWpGaD
Etodolac—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	4.49e-05	0.00038	CcSEcCtD
Etodolac—Urticaria—Cyclosporine—psoriasis	4.47e-05	0.000379	CcSEcCtD
Etodolac—Myalgia—Betamethasone—psoriasis	4.46e-05	0.000378	CcSEcCtD
Etodolac—Myalgia—Dexamethasone—psoriasis	4.46e-05	0.000378	CcSEcCtD
Etodolac—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	4.46e-05	0.00185	CbGpPWpGaD
Etodolac—Abdominal pain—Cyclosporine—psoriasis	4.45e-05	0.000377	CcSEcCtD
Etodolac—Body temperature increased—Cyclosporine—psoriasis	4.45e-05	0.000377	CcSEcCtD
Etodolac—Anxiety—Betamethasone—psoriasis	4.44e-05	0.000376	CcSEcCtD
Etodolac—Anxiety—Dexamethasone—psoriasis	4.44e-05	0.000376	CcSEcCtD
Etodolac—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	4.43e-05	0.00184	CbGpPWpGaD
Etodolac—RXRA—Metabolism—NDUFA5—psoriasis	4.43e-05	0.00184	CbGpPWpGaD
Etodolac—Vomiting—Mycophenolic acid—psoriasis	4.42e-05	0.000375	CcSEcCtD
Etodolac—Discomfort—Betamethasone—psoriasis	4.41e-05	0.000373	CcSEcCtD
Etodolac—Discomfort—Dexamethasone—psoriasis	4.41e-05	0.000373	CcSEcCtD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	4.4e-05	0.00183	CbGpPWpGaD
Etodolac—Dyspepsia—Hydrocortisone—psoriasis	4.4e-05	0.000373	CcSEcCtD
Etodolac—Haemoglobin—Methotrexate—psoriasis	4.4e-05	0.000373	CcSEcCtD
Etodolac—Rash—Mycophenolic acid—psoriasis	4.39e-05	0.000372	CcSEcCtD
Etodolac—Dermatitis—Mycophenolic acid—psoriasis	4.38e-05	0.000371	CcSEcCtD
Etodolac—Pain—Prednisolone—psoriasis	4.38e-05	0.000371	CcSEcCtD
Etodolac—Haemorrhage—Methotrexate—psoriasis	4.38e-05	0.000371	CcSEcCtD
Etodolac—Hepatitis—Methotrexate—psoriasis	4.38e-05	0.000371	CcSEcCtD
Etodolac—Urticaria—Mycophenolate mofetil—psoriasis	4.36e-05	0.000369	CcSEcCtD
Etodolac—Headache—Mycophenolic acid—psoriasis	4.36e-05	0.000369	CcSEcCtD
Etodolac—Decreased appetite—Hydrocortisone—psoriasis	4.35e-05	0.000368	CcSEcCtD
Etodolac—Pharyngitis—Methotrexate—psoriasis	4.35e-05	0.000368	CcSEcCtD
Etodolac—Body temperature increased—Mycophenolate mofetil—psoriasis	4.34e-05	0.000368	CcSEcCtD
Etodolac—Abdominal pain—Mycophenolate mofetil—psoriasis	4.34e-05	0.000368	CcSEcCtD
Etodolac—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	4.32e-05	0.0018	CbGpPWpGaD
Etodolac—Fatigue—Hydrocortisone—psoriasis	4.31e-05	0.000365	CcSEcCtD
Etodolac—Vision blurred—Prednisone—psoriasis	4.3e-05	0.000364	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Triamcinolone—psoriasis	4.29e-05	0.000363	CcSEcCtD
Etodolac—Pain—Hydrocortisone—psoriasis	4.28e-05	0.000362	CcSEcCtD
Etodolac—Anaphylactic shock—Dexamethasone—psoriasis	4.27e-05	0.000362	CcSEcCtD
Etodolac—Anaphylactic shock—Betamethasone—psoriasis	4.27e-05	0.000362	CcSEcCtD
Etodolac—Oedema—Betamethasone—psoriasis	4.27e-05	0.000362	CcSEcCtD
Etodolac—Oedema—Dexamethasone—psoriasis	4.27e-05	0.000362	CcSEcCtD
Etodolac—Insomnia—Triamcinolone—psoriasis	4.26e-05	0.000361	CcSEcCtD
Etodolac—Infection—Dexamethasone—psoriasis	4.25e-05	0.00036	CcSEcCtD
Etodolac—Infection—Betamethasone—psoriasis	4.25e-05	0.00036	CcSEcCtD
Etodolac—Ill-defined disorder—Prednisone—psoriasis	4.23e-05	0.000358	CcSEcCtD
Etodolac—Paraesthesia—Triamcinolone—psoriasis	4.23e-05	0.000358	CcSEcCtD
Etodolac—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	4.22e-05	0.00176	CbGpPWpGaD
Etodolac—Feeling abnormal—Prednisolone—psoriasis	4.22e-05	0.000357	CcSEcCtD
Etodolac—Visual impairment—Methotrexate—psoriasis	4.22e-05	0.000357	CcSEcCtD
Etodolac—Anaemia—Prednisone—psoriasis	4.22e-05	0.000357	CcSEcCtD
Etodolac—Shock—Dexamethasone—psoriasis	4.21e-05	0.000356	CcSEcCtD
Etodolac—Shock—Betamethasone—psoriasis	4.21e-05	0.000356	CcSEcCtD
Etodolac—Dyspnoea—Triamcinolone—psoriasis	4.2e-05	0.000356	CcSEcCtD
Etodolac—Thrombocytopenia—Betamethasone—psoriasis	4.18e-05	0.000354	CcSEcCtD
Etodolac—Thrombocytopenia—Dexamethasone—psoriasis	4.18e-05	0.000354	CcSEcCtD
Etodolac—Tachycardia—Betamethasone—psoriasis	4.17e-05	0.000353	CcSEcCtD
Etodolac—Tachycardia—Dexamethasone—psoriasis	4.17e-05	0.000353	CcSEcCtD
Etodolac—Angioedema—Prednisone—psoriasis	4.17e-05	0.000353	CcSEcCtD
Etodolac—Hypersensitivity—Cyclosporine—psoriasis	4.15e-05	0.000351	CcSEcCtD
Etodolac—Dyspepsia—Triamcinolone—psoriasis	4.15e-05	0.000351	CcSEcCtD
Etodolac—Erythema multiforme—Methotrexate—psoriasis	4.14e-05	0.000351	CcSEcCtD
Etodolac—Nausea—Mycophenolic acid—psoriasis	4.13e-05	0.00035	CcSEcCtD
Etodolac—Hyperhidrosis—Betamethasone—psoriasis	4.13e-05	0.00035	CcSEcCtD
Etodolac—Hyperhidrosis—Dexamethasone—psoriasis	4.13e-05	0.00035	CcSEcCtD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.13e-05	0.00172	CbGpPWpGaD
Etodolac—Feeling abnormal—Hydrocortisone—psoriasis	4.12e-05	0.000349	CcSEcCtD
Etodolac—RXRA—Transmembrane transport of small molecules—CP—psoriasis	4.12e-05	0.00171	CbGpPWpGaD
Etodolac—Malaise—Prednisone—psoriasis	4.11e-05	0.000348	CcSEcCtD
Etodolac—Vertigo—Prednisone—psoriasis	4.1e-05	0.000347	CcSEcCtD
Etodolac—ALB—Selenium Micronutrient Network—CRP—psoriasis	4.09e-05	0.0017	CbGpPWpGaD
Etodolac—Gastrointestinal pain—Hydrocortisone—psoriasis	4.09e-05	0.000346	CcSEcCtD
Etodolac—Syncope—Prednisone—psoriasis	4.09e-05	0.000346	CcSEcCtD
Etodolac—Tinnitus—Methotrexate—psoriasis	4.08e-05	0.000346	CcSEcCtD
Etodolac—Anorexia—Betamethasone—psoriasis	4.07e-05	0.000345	CcSEcCtD
Etodolac—Anorexia—Dexamethasone—psoriasis	4.07e-05	0.000345	CcSEcCtD
Etodolac—Urticaria—Prednisolone—psoriasis	4.07e-05	0.000345	CcSEcCtD
Etodolac—Fatigue—Triamcinolone—psoriasis	4.06e-05	0.000344	CcSEcCtD
Etodolac—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.05e-05	0.000343	CcSEcCtD
Etodolac—Asthenia—Cyclosporine—psoriasis	4.04e-05	0.000342	CcSEcCtD
Etodolac—UGT2B7—Metabolism—CYP2S1—psoriasis	4.04e-05	0.00168	CbGpPWpGaD
Etodolac—Pain—Triamcinolone—psoriasis	4.03e-05	0.000341	CcSEcCtD
Etodolac—Loss of consciousness—Prednisone—psoriasis	4.01e-05	0.000339	CcSEcCtD
Etodolac—Hypotension—Dexamethasone—psoriasis	3.99e-05	0.000338	CcSEcCtD
Etodolac—Hypotension—Betamethasone—psoriasis	3.99e-05	0.000338	CcSEcCtD
Etodolac—Pruritus—Cyclosporine—psoriasis	3.98e-05	0.000337	CcSEcCtD
Etodolac—Urticaria—Hydrocortisone—psoriasis	3.97e-05	0.000337	CcSEcCtD
Etodolac—Abdominal pain—Hydrocortisone—psoriasis	3.95e-05	0.000335	CcSEcCtD
Etodolac—Body temperature increased—Hydrocortisone—psoriasis	3.95e-05	0.000335	CcSEcCtD
Etodolac—Convulsion—Prednisone—psoriasis	3.95e-05	0.000335	CcSEcCtD
Etodolac—Asthenia—Mycophenolate mofetil—psoriasis	3.94e-05	0.000334	CcSEcCtD
Etodolac—Hypertension—Prednisone—psoriasis	3.94e-05	0.000333	CcSEcCtD
Etodolac—Chills—Methotrexate—psoriasis	3.93e-05	0.000333	CcSEcCtD
Etodolac—RXRA—Transmembrane transport of small molecules—CARM1—psoriasis	3.93e-05	0.00163	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—LEP—psoriasis	3.92e-05	0.00163	CbGpPWpGaD
Etodolac—Musculoskeletal discomfort—Betamethasone—psoriasis	3.89e-05	0.00033	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Dexamethasone—psoriasis	3.89e-05	0.00033	CcSEcCtD
Etodolac—Pruritus—Mycophenolate mofetil—psoriasis	3.89e-05	0.000329	CcSEcCtD
Etodolac—Myalgia—Prednisone—psoriasis	3.88e-05	0.000329	CcSEcCtD
Etodolac—Arthralgia—Prednisone—psoriasis	3.88e-05	0.000329	CcSEcCtD
Etodolac—Feeling abnormal—Triamcinolone—psoriasis	3.88e-05	0.000329	CcSEcCtD
Etodolac—Anxiety—Prednisone—psoriasis	3.87e-05	0.000328	CcSEcCtD
Etodolac—Alopecia—Methotrexate—psoriasis	3.87e-05	0.000328	CcSEcCtD
Etodolac—Insomnia—Dexamethasone—psoriasis	3.87e-05	0.000327	CcSEcCtD
Etodolac—Insomnia—Betamethasone—psoriasis	3.87e-05	0.000327	CcSEcCtD
Etodolac—UGT1A9—Metabolism—NDUFA5—psoriasis	3.86e-05	0.0016	CbGpPWpGaD
Etodolac—Diarrhoea—Cyclosporine—psoriasis	3.85e-05	0.000326	CcSEcCtD
Etodolac—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.85e-05	0.0016	CbGpPWpGaD
Etodolac—Paraesthesia—Dexamethasone—psoriasis	3.84e-05	0.000325	CcSEcCtD
Etodolac—Paraesthesia—Betamethasone—psoriasis	3.84e-05	0.000325	CcSEcCtD
Etodolac—Discomfort—Prednisone—psoriasis	3.84e-05	0.000325	CcSEcCtD
Etodolac—Hypersensitivity—Prednisolone—psoriasis	3.77e-05	0.00032	CcSEcCtD
Etodolac—RXRA—Metabolism—CYP2S1—psoriasis	3.77e-05	0.00157	CbGpPWpGaD
Etodolac—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	3.76e-05	0.00157	CbGpPWpGaD
Etodolac—Dyspepsia—Dexamethasone—psoriasis	3.76e-05	0.000319	CcSEcCtD
Etodolac—Dyspepsia—Betamethasone—psoriasis	3.76e-05	0.000319	CcSEcCtD
Etodolac—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	3.76e-05	0.00156	CbGpPWpGaD
Etodolac—Diarrhoea—Mycophenolate mofetil—psoriasis	3.76e-05	0.000318	CcSEcCtD
Etodolac—Urticaria—Triamcinolone—psoriasis	3.74e-05	0.000317	CcSEcCtD
Etodolac—Dysgeusia—Methotrexate—psoriasis	3.73e-05	0.000316	CcSEcCtD
Etodolac—Body temperature increased—Triamcinolone—psoriasis	3.72e-05	0.000315	CcSEcCtD
Etodolac—Dizziness—Cyclosporine—psoriasis	3.72e-05	0.000315	CcSEcCtD
Etodolac—Anaphylactic shock—Prednisone—psoriasis	3.72e-05	0.000315	CcSEcCtD
Etodolac—Oedema—Prednisone—psoriasis	3.72e-05	0.000315	CcSEcCtD
Etodolac—Decreased appetite—Dexamethasone—psoriasis	3.72e-05	0.000315	CcSEcCtD
Etodolac—Decreased appetite—Betamethasone—psoriasis	3.72e-05	0.000315	CcSEcCtD
Etodolac—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	3.71e-05	0.00154	CbGpPWpGaD
Etodolac—Infection—Prednisone—psoriasis	3.7e-05	0.000313	CcSEcCtD
Etodolac—ALB—SLC-mediated transmembrane transport—CP—psoriasis	3.69e-05	0.00154	CbGpPWpGaD
Etodolac—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	3.69e-05	0.00153	CbGpPWpGaD
Etodolac—Hypersensitivity—Hydrocortisone—psoriasis	3.69e-05	0.000312	CcSEcCtD
Etodolac—Fatigue—Betamethasone—psoriasis	3.69e-05	0.000312	CcSEcCtD
Etodolac—Fatigue—Dexamethasone—psoriasis	3.69e-05	0.000312	CcSEcCtD
Etodolac—PTGS2—Spinal Cord Injury—ICAM1—psoriasis	3.68e-05	0.00153	CbGpPWpGaD
Etodolac—Shock—Prednisone—psoriasis	3.66e-05	0.00031	CcSEcCtD
Etodolac—Pain—Betamethasone—psoriasis	3.66e-05	0.00031	CcSEcCtD
Etodolac—Pain—Dexamethasone—psoriasis	3.66e-05	0.00031	CcSEcCtD
Etodolac—PTGS2—Spinal Cord Injury—NOS2—psoriasis	3.65e-05	0.00152	CbGpPWpGaD
Etodolac—Tachycardia—Prednisone—psoriasis	3.63e-05	0.000308	CcSEcCtD
Etodolac—Dizziness—Mycophenolate mofetil—psoriasis	3.63e-05	0.000308	CcSEcCtD
Etodolac—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	3.61e-05	0.0015	CbGpPWpGaD
Etodolac—ALB—Folate Metabolism—IFNG—psoriasis	3.6e-05	0.0015	CbGpPWpGaD
Etodolac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	3.6e-05	0.0015	CbGpPWpGaD
Etodolac—Hyperhidrosis—Prednisone—psoriasis	3.6e-05	0.000305	CcSEcCtD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.6e-05	0.0015	CbGpPWpGaD
Etodolac—Vision blurred—Methotrexate—psoriasis	3.59e-05	0.000304	CcSEcCtD
Etodolac—Asthenia—Hydrocortisone—psoriasis	3.59e-05	0.000304	CcSEcCtD
Etodolac—Vomiting—Cyclosporine—psoriasis	3.58e-05	0.000303	CcSEcCtD
Etodolac—Rash—Cyclosporine—psoriasis	3.55e-05	0.000301	CcSEcCtD
Etodolac—Anorexia—Prednisone—psoriasis	3.55e-05	0.0003	CcSEcCtD
Etodolac—PTGS2—C-MYB transcription factor network—CD4—psoriasis	3.55e-05	0.00148	CbGpPWpGaD
Etodolac—Dermatitis—Cyclosporine—psoriasis	3.55e-05	0.0003	CcSEcCtD
Etodolac—Pruritus—Hydrocortisone—psoriasis	3.54e-05	0.0003	CcSEcCtD
Etodolac—PTGS2—Selenium Micronutrient Network—IFNG—psoriasis	3.54e-05	0.00147	CbGpPWpGaD
Etodolac—Ill-defined disorder—Methotrexate—psoriasis	3.54e-05	0.0003	CcSEcCtD
Etodolac—Headache—Cyclosporine—psoriasis	3.53e-05	0.000299	CcSEcCtD
Etodolac—Anaemia—Methotrexate—psoriasis	3.52e-05	0.000298	CcSEcCtD
Etodolac—Feeling abnormal—Dexamethasone—psoriasis	3.52e-05	0.000298	CcSEcCtD
Etodolac—Feeling abnormal—Betamethasone—psoriasis	3.52e-05	0.000298	CcSEcCtD
Etodolac—Gastrointestinal pain—Dexamethasone—psoriasis	3.5e-05	0.000296	CcSEcCtD
Etodolac—Gastrointestinal pain—Betamethasone—psoriasis	3.5e-05	0.000296	CcSEcCtD
Etodolac—Vomiting—Mycophenolate mofetil—psoriasis	3.49e-05	0.000296	CcSEcCtD
Etodolac—Hypersensitivity—Triamcinolone—psoriasis	3.47e-05	0.000294	CcSEcCtD
Etodolac—Rash—Mycophenolate mofetil—psoriasis	3.46e-05	0.000293	CcSEcCtD
Etodolac—Dermatitis—Mycophenolate mofetil—psoriasis	3.46e-05	0.000293	CcSEcCtD
Etodolac—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	3.45e-05	0.00143	CbGpPWpGaD
Etodolac—Headache—Mycophenolate mofetil—psoriasis	3.44e-05	0.000291	CcSEcCtD
Etodolac—Malaise—Methotrexate—psoriasis	3.44e-05	0.000291	CcSEcCtD
Etodolac—RXRA—Adipogenesis—STAT3—psoriasis	3.44e-05	0.00143	CbGpPWpGaD
Etodolac—Vertigo—Methotrexate—psoriasis	3.42e-05	0.00029	CcSEcCtD
Etodolac—Diarrhoea—Hydrocortisone—psoriasis	3.42e-05	0.00029	CcSEcCtD
Etodolac—Leukopenia—Methotrexate—psoriasis	3.41e-05	0.000289	CcSEcCtD
Etodolac—Urticaria—Dexamethasone—psoriasis	3.4e-05	0.000288	CcSEcCtD
Etodolac—Urticaria—Betamethasone—psoriasis	3.4e-05	0.000288	CcSEcCtD
Etodolac—Musculoskeletal discomfort—Prednisone—psoriasis	3.39e-05	0.000287	CcSEcCtD
Etodolac—Dizziness—Prednisolone—psoriasis	3.39e-05	0.000287	CcSEcCtD
Etodolac—Asthenia—Triamcinolone—psoriasis	3.38e-05	0.000286	CcSEcCtD
Etodolac—Abdominal pain—Betamethasone—psoriasis	3.38e-05	0.000286	CcSEcCtD
Etodolac—Abdominal pain—Dexamethasone—psoriasis	3.38e-05	0.000286	CcSEcCtD
Etodolac—Body temperature increased—Dexamethasone—psoriasis	3.38e-05	0.000286	CcSEcCtD
Etodolac—Body temperature increased—Betamethasone—psoriasis	3.38e-05	0.000286	CcSEcCtD
Etodolac—Insomnia—Prednisone—psoriasis	3.37e-05	0.000285	CcSEcCtD
Etodolac—Nausea—Cyclosporine—psoriasis	3.34e-05	0.000283	CcSEcCtD
Etodolac—Paraesthesia—Prednisone—psoriasis	3.34e-05	0.000283	CcSEcCtD
Etodolac—Pruritus—Triamcinolone—psoriasis	3.33e-05	0.000282	CcSEcCtD
Etodolac—Dizziness—Hydrocortisone—psoriasis	3.31e-05	0.00028	CcSEcCtD
Etodolac—Convulsion—Methotrexate—psoriasis	3.3e-05	0.00028	CcSEcCtD
Etodolac—UGT1A9—Metabolism—CYP2S1—psoriasis	3.28e-05	0.00136	CbGpPWpGaD
Etodolac—Dyspepsia—Prednisone—psoriasis	3.28e-05	0.000277	CcSEcCtD
Etodolac—Nausea—Mycophenolate mofetil—psoriasis	3.26e-05	0.000276	CcSEcCtD
Etodolac—Arthralgia—Methotrexate—psoriasis	3.25e-05	0.000275	CcSEcCtD
Etodolac—Myalgia—Methotrexate—psoriasis	3.25e-05	0.000275	CcSEcCtD
Etodolac—Decreased appetite—Prednisone—psoriasis	3.24e-05	0.000274	CcSEcCtD
Etodolac—Rash—Prednisolone—psoriasis	3.23e-05	0.000274	CcSEcCtD
Etodolac—Dermatitis—Prednisolone—psoriasis	3.23e-05	0.000273	CcSEcCtD
Etodolac—Fatigue—Prednisone—psoriasis	3.21e-05	0.000272	CcSEcCtD
Etodolac—Headache—Prednisolone—psoriasis	3.21e-05	0.000272	CcSEcCtD
Etodolac—Discomfort—Methotrexate—psoriasis	3.21e-05	0.000272	CcSEcCtD
Etodolac—Constipation—Prednisone—psoriasis	3.18e-05	0.00027	CcSEcCtD
Etodolac—Vomiting—Hydrocortisone—psoriasis	3.18e-05	0.000269	CcSEcCtD
Etodolac—Rash—Hydrocortisone—psoriasis	3.15e-05	0.000267	CcSEcCtD
Etodolac—Dermatitis—Hydrocortisone—psoriasis	3.15e-05	0.000267	CcSEcCtD
Etodolac—PTGS1—Metabolism—NDUFA5—psoriasis	3.14e-05	0.00131	CbGpPWpGaD
Etodolac—Confusional state—Methotrexate—psoriasis	3.14e-05	0.000266	CcSEcCtD
Etodolac—Headache—Hydrocortisone—psoriasis	3.13e-05	0.000265	CcSEcCtD
Etodolac—Dizziness—Triamcinolone—psoriasis	3.12e-05	0.000264	CcSEcCtD
Etodolac—Anaphylactic shock—Methotrexate—psoriasis	3.11e-05	0.000263	CcSEcCtD
Etodolac—Infection—Methotrexate—psoriasis	3.09e-05	0.000262	CcSEcCtD
Etodolac—Feeling abnormal—Prednisone—psoriasis	3.07e-05	0.00026	CcSEcCtD
Etodolac—Asthenia—Betamethasone—psoriasis	3.07e-05	0.00026	CcSEcCtD
Etodolac—Asthenia—Dexamethasone—psoriasis	3.07e-05	0.00026	CcSEcCtD
Etodolac—Thrombocytopenia—Methotrexate—psoriasis	3.05e-05	0.000258	CcSEcCtD
Etodolac—Gastrointestinal pain—Prednisone—psoriasis	3.04e-05	0.000258	CcSEcCtD
Etodolac—Nausea—Prednisolone—psoriasis	3.04e-05	0.000258	CcSEcCtD
Etodolac—Pruritus—Betamethasone—psoriasis	3.02e-05	0.000256	CcSEcCtD
Etodolac—Pruritus—Dexamethasone—psoriasis	3.02e-05	0.000256	CcSEcCtD
Etodolac—Hyperhidrosis—Methotrexate—psoriasis	3.01e-05	0.000255	CcSEcCtD
Etodolac—ALB—Folate Metabolism—NFKB1—psoriasis	3e-05	0.00125	CbGpPWpGaD
Etodolac—Vomiting—Triamcinolone—psoriasis	3e-05	0.000254	CcSEcCtD
Etodolac—RXRA—Adipogenesis—TNF—psoriasis	2.97e-05	0.00124	CbGpPWpGaD
Etodolac—Nausea—Hydrocortisone—psoriasis	2.97e-05	0.000252	CcSEcCtD
Etodolac—Rash—Triamcinolone—psoriasis	2.97e-05	0.000252	CcSEcCtD
Etodolac—Dermatitis—Triamcinolone—psoriasis	2.97e-05	0.000251	CcSEcCtD
Etodolac—Anorexia—Methotrexate—psoriasis	2.97e-05	0.000251	CcSEcCtD
Etodolac—Urticaria—Prednisone—psoriasis	2.96e-05	0.00025	CcSEcCtD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.95e-05	0.00123	CbGpPWpGaD
Etodolac—Headache—Triamcinolone—psoriasis	2.95e-05	0.00025	CcSEcCtD
Etodolac—PTGS2—Selenium Micronutrient Network—NFKB1—psoriasis	2.95e-05	0.00123	CbGpPWpGaD
Etodolac—Abdominal pain—Prednisone—psoriasis	2.94e-05	0.000249	CcSEcCtD
Etodolac—Body temperature increased—Prednisone—psoriasis	2.94e-05	0.000249	CcSEcCtD
Etodolac—RXRA—Generic Transcription Pathway—VDR—psoriasis	2.93e-05	0.00122	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.93e-05	0.00122	CbGpPWpGaD
Etodolac—Diarrhoea—Dexamethasone—psoriasis	2.92e-05	0.000248	CcSEcCtD
Etodolac—Diarrhoea—Betamethasone—psoriasis	2.92e-05	0.000248	CcSEcCtD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.92e-05	0.00121	CbGpPWpGaD
Etodolac—Hypotension—Methotrexate—psoriasis	2.91e-05	0.000246	CcSEcCtD
Etodolac—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	2.89e-05	0.0012	CbGpPWpGaD
Etodolac—ALB—Vitamin B12 Metabolism—TNF—psoriasis	2.87e-05	0.00119	CbGpPWpGaD
Etodolac—ALB—Selenium Micronutrient Network—IFNG—psoriasis	2.86e-05	0.00119	CbGpPWpGaD
Etodolac—Musculoskeletal discomfort—Methotrexate—psoriasis	2.83e-05	0.00024	CcSEcCtD
Etodolac—Dizziness—Betamethasone—psoriasis	2.83e-05	0.000239	CcSEcCtD
Etodolac—Dizziness—Dexamethasone—psoriasis	2.83e-05	0.000239	CcSEcCtD
Etodolac—Insomnia—Methotrexate—psoriasis	2.81e-05	0.000238	CcSEcCtD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.81e-05	0.00117	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—IFNG—psoriasis	2.8e-05	0.00116	CbGpPWpGaD
Etodolac—Nausea—Triamcinolone—psoriasis	2.8e-05	0.000237	CcSEcCtD
Etodolac—Paraesthesia—Methotrexate—psoriasis	2.79e-05	0.000237	CcSEcCtD
Etodolac—Dyspnoea—Methotrexate—psoriasis	2.77e-05	0.000235	CcSEcCtD
Etodolac—Somnolence—Methotrexate—psoriasis	2.77e-05	0.000234	CcSEcCtD
Etodolac—Hypersensitivity—Prednisone—psoriasis	2.74e-05	0.000232	CcSEcCtD
Etodolac—Dyspepsia—Methotrexate—psoriasis	2.74e-05	0.000232	CcSEcCtD
Etodolac—Vomiting—Dexamethasone—psoriasis	2.72e-05	0.00023	CcSEcCtD
Etodolac—Vomiting—Betamethasone—psoriasis	2.72e-05	0.00023	CcSEcCtD
Etodolac—Decreased appetite—Methotrexate—psoriasis	2.7e-05	0.000229	CcSEcCtD
Etodolac—Rash—Betamethasone—psoriasis	2.69e-05	0.000228	CcSEcCtD
Etodolac—Rash—Dexamethasone—psoriasis	2.69e-05	0.000228	CcSEcCtD
Etodolac—Dermatitis—Dexamethasone—psoriasis	2.69e-05	0.000228	CcSEcCtD
Etodolac—Dermatitis—Betamethasone—psoriasis	2.69e-05	0.000228	CcSEcCtD
Etodolac—Fatigue—Methotrexate—psoriasis	2.68e-05	0.000227	CcSEcCtD
Etodolac—Headache—Dexamethasone—psoriasis	2.68e-05	0.000227	CcSEcCtD
Etodolac—Headache—Betamethasone—psoriasis	2.68e-05	0.000227	CcSEcCtD
Etodolac—PTGS1—Metabolism—CYP2S1—psoriasis	2.67e-05	0.00111	CbGpPWpGaD
Etodolac—Asthenia—Prednisone—psoriasis	2.67e-05	0.000226	CcSEcCtD
Etodolac—Pain—Methotrexate—psoriasis	2.66e-05	0.000225	CcSEcCtD
Etodolac—Pruritus—Prednisone—psoriasis	2.63e-05	0.000223	CcSEcCtD
Etodolac—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	2.6e-05	0.00108	CbGpPWpGaD
Etodolac—Feeling abnormal—Methotrexate—psoriasis	2.56e-05	0.000217	CcSEcCtD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.55e-05	0.00106	CbGpPWpGaD
Etodolac—Diarrhoea—Prednisone—psoriasis	2.55e-05	0.000216	CcSEcCtD
Etodolac—Gastrointestinal pain—Methotrexate—psoriasis	2.54e-05	0.000215	CcSEcCtD
Etodolac—Nausea—Dexamethasone—psoriasis	2.54e-05	0.000215	CcSEcCtD
Etodolac—Nausea—Betamethasone—psoriasis	2.54e-05	0.000215	CcSEcCtD
Etodolac—PTGS2—Metabolism—NDUFA5—psoriasis	2.5e-05	0.00104	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.48e-05	0.00103	CbGpPWpGaD
Etodolac—Urticaria—Methotrexate—psoriasis	2.47e-05	0.000209	CcSEcCtD
Etodolac—Dizziness—Prednisone—psoriasis	2.46e-05	0.000208	CcSEcCtD
Etodolac—Abdominal pain—Methotrexate—psoriasis	2.46e-05	0.000208	CcSEcCtD
Etodolac—Body temperature increased—Methotrexate—psoriasis	2.46e-05	0.000208	CcSEcCtD
Etodolac—RXRA—Adipogenesis—IL6—psoriasis	2.4e-05	0.000998	CbGpPWpGaD
Etodolac—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	2.38e-05	0.000991	CbGpPWpGaD
Etodolac—Vomiting—Prednisone—psoriasis	2.37e-05	0.0002	CcSEcCtD
Etodolac—RXRA—Gene Expression—CARM1—psoriasis	2.36e-05	0.000984	CbGpPWpGaD
Etodolac—Rash—Prednisone—psoriasis	2.35e-05	0.000199	CcSEcCtD
Etodolac—Dermatitis—Prednisone—psoriasis	2.34e-05	0.000199	CcSEcCtD
Etodolac—ALB—Platelet degranulation—VEGFA—psoriasis	2.33e-05	0.000971	CbGpPWpGaD
Etodolac—ALB—Folate Metabolism—TNF—psoriasis	2.33e-05	0.00097	CbGpPWpGaD
Etodolac—Headache—Prednisone—psoriasis	2.33e-05	0.000197	CcSEcCtD
Etodolac—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	2.33e-05	0.000969	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.33e-05	0.000968	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—CARM1—psoriasis	2.32e-05	0.000964	CbGpPWpGaD
Etodolac—ALB—Vitamin B12 Metabolism—IL6—psoriasis	2.31e-05	0.000963	CbGpPWpGaD
Etodolac—Hypersensitivity—Methotrexate—psoriasis	2.29e-05	0.000194	CcSEcCtD
Etodolac—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	2.29e-05	0.000953	CbGpPWpGaD
Etodolac—ALB—Hemostasis—ITGAL—psoriasis	2.25e-05	0.000934	CbGpPWpGaD
Etodolac—Asthenia—Methotrexate—psoriasis	2.23e-05	0.000189	CcSEcCtD
Etodolac—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	2.22e-05	0.000925	CbGpPWpGaD
Etodolac—Nausea—Prednisone—psoriasis	2.21e-05	0.000187	CcSEcCtD
Etodolac—RXRA—Developmental Biology—LEP—psoriasis	2.21e-05	0.000919	CbGpPWpGaD
Etodolac—Pruritus—Methotrexate—psoriasis	2.2e-05	0.000186	CcSEcCtD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.19e-05	0.000909	CbGpPWpGaD
Etodolac—Diarrhoea—Methotrexate—psoriasis	2.13e-05	0.00018	CcSEcCtD
Etodolac—PTGS2—Metabolism—CYP2S1—psoriasis	2.12e-05	0.000883	CbGpPWpGaD
Etodolac—Dizziness—Methotrexate—psoriasis	2.06e-05	0.000174	CcSEcCtD
Etodolac—ALB—Folate Metabolism—TP53—psoriasis	2.06e-05	0.000856	CbGpPWpGaD
Etodolac—RXRA—Generic Transcription Pathway—PPARG—psoriasis	2.04e-05	0.000851	CbGpPWpGaD
Etodolac—ALB—Metabolism—NDUFA5—psoriasis	2.02e-05	0.00084	CbGpPWpGaD
Etodolac—Vomiting—Methotrexate—psoriasis	1.98e-05	0.000168	CcSEcCtD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.97e-05	0.000821	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—CARM1—psoriasis	1.97e-05	0.00082	CbGpPWpGaD
Etodolac—Rash—Methotrexate—psoriasis	1.96e-05	0.000166	CcSEcCtD
Etodolac—Dermatitis—Methotrexate—psoriasis	1.96e-05	0.000166	CcSEcCtD
Etodolac—Headache—Methotrexate—psoriasis	1.95e-05	0.000165	CcSEcCtD
Etodolac—RXRA—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.93e-05	0.000802	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—PPARG—psoriasis	1.92e-05	0.000801	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.88e-05	0.000783	CbGpPWpGaD
Etodolac—ALB—Folate Metabolism—IL6—psoriasis	1.88e-05	0.000783	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—CP—psoriasis	1.88e-05	0.000781	CbGpPWpGaD
Etodolac—ALB—Selenium Micronutrient Network—TNF—psoriasis	1.85e-05	0.000771	CbGpPWpGaD
Etodolac—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	1.85e-05	0.000769	CbGpPWpGaD
Etodolac—Nausea—Methotrexate—psoriasis	1.85e-05	0.000156	CcSEcCtD
Etodolac—RXRA—Metabolism—CARM1—psoriasis	1.84e-05	0.000765	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—TNF—psoriasis	1.81e-05	0.000754	CbGpPWpGaD
Etodolac—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	1.79e-05	0.000745	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.72e-05	0.000715	CbGpPWpGaD
Etodolac—RXRA—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.72e-05	0.000715	CbGpPWpGaD
Etodolac—ALB—Metabolism—CYP2S1—psoriasis	1.72e-05	0.000714	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—TYK2—psoriasis	1.69e-05	0.000702	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—NDUFA5—psoriasis	1.65e-05	0.000688	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.65e-05	0.000685	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—CARM1—psoriasis	1.6e-05	0.000666	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—TP53—psoriasis	1.6e-05	0.000664	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.58e-05	0.000659	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.54e-05	0.000641	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.5e-05	0.000623	CbGpPWpGaD
Etodolac—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.5e-05	0.000622	CbGpPWpGaD
Etodolac—PTGS2—Spinal Cord Injury—IL6—psoriasis	1.46e-05	0.000608	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.44e-05	0.000598	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—CAT—psoriasis	1.43e-05	0.000593	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—VDR—psoriasis	1.41e-05	0.000587	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CYP2S1—psoriasis	1.41e-05	0.000585	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.4e-05	0.000583	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—NFKB1—psoriasis	1.31e-05	0.000547	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—CARM1—psoriasis	1.31e-05	0.000543	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.23e-05	0.000513	CbGpPWpGaD
Etodolac—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.22e-05	0.000508	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—CAT—psoriasis	1.21e-05	0.000504	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—VEGFA—psoriasis	1.19e-05	0.000496	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—STAT3—psoriasis	1.18e-05	0.000491	CbGpPWpGaD
Etodolac—RXRA—Metabolism—CAT—psoriasis	1.13e-05	0.000471	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.11e-05	0.000463	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—APOE—psoriasis	1.11e-05	0.000461	CbGpPWpGaD
Etodolac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.09e-05	0.000452	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CARM1—psoriasis	1.04e-05	0.000431	CbGpPWpGaD
Etodolac—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.04e-05	0.000431	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—TNF—psoriasis	1.02e-05	0.000425	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—CAT—psoriasis	9.85e-06	0.00041	CbGpPWpGaD
Etodolac—RXRA—Gene Expression—PPARG—psoriasis	9.84e-06	0.00041	CbGpPWpGaD
Etodolac—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.69e-06	0.000403	CbGpPWpGaD
Etodolac—UGT1A3—Metabolism—PPARG—psoriasis	9.65e-06	0.000401	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—APOE—psoriasis	9.42e-06	0.000392	CbGpPWpGaD
Etodolac—ALB—Hemostasis—NOS2—psoriasis	9.21e-06	0.000383	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	9e-06	0.000374	CbGpPWpGaD
Etodolac—RXRA—Metabolism—APOE—psoriasis	8.79e-06	0.000366	CbGpPWpGaD
Etodolac—ALB—Metabolism—CARM1—psoriasis	8.39e-06	0.000349	CbGpPWpGaD
Etodolac—RXRA—Developmental Biology—IL6—psoriasis	8.25e-06	0.000343	CbGpPWpGaD
Etodolac—UGT2B7—Metabolism—PPARG—psoriasis	8.21e-06	0.000341	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—CAT—psoriasis	8.03e-06	0.000334	CbGpPWpGaD
Etodolac—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.84e-06	0.000326	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—APOE—psoriasis	7.66e-06	0.000318	CbGpPWpGaD
Etodolac—RXRA—Metabolism—PPARG—psoriasis	7.66e-06	0.000318	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.37e-06	0.000306	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CARM1—psoriasis	6.87e-06	0.000286	CbGpPWpGaD
Etodolac—UGT1A9—Metabolism—PPARG—psoriasis	6.67e-06	0.000277	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.42e-06	0.000267	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—CAT—psoriasis	6.38e-06	0.000265	CbGpPWpGaD
Etodolac—PTGS2—Disease—HLA-A—psoriasis	6.34e-06	0.000264	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—APOE—psoriasis	6.24e-06	0.00026	CbGpPWpGaD
Etodolac—PTGS2—Disease—APOE—psoriasis	5.92e-06	0.000246	CbGpPWpGaD
Etodolac—PTGS2—Disease—NOS2—psoriasis	5.51e-06	0.000229	CbGpPWpGaD
Etodolac—PTGS1—Metabolism—PPARG—psoriasis	5.44e-06	0.000226	CbGpPWpGaD
Etodolac—ALB—Hemostasis—VEGFA—psoriasis	5.34e-06	0.000222	CbGpPWpGaD
Etodolac—ALB—Metabolism—CAT—psoriasis	5.16e-06	0.000215	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—APOE—psoriasis	4.95e-06	0.000206	CbGpPWpGaD
Etodolac—PTGS2—Disease—TYK2—psoriasis	4.52e-06	0.000188	CbGpPWpGaD
Etodolac—PTGS2—Metabolism—PPARG—psoriasis	4.32e-06	0.00018	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—CAT—psoriasis	4.22e-06	0.000176	CbGpPWpGaD
Etodolac—PTGS2—Disease—CD4—psoriasis	4.08e-06	0.00017	CbGpPWpGaD
Etodolac—ALB—Hemostasis—TP53—psoriasis	4.03e-06	0.000168	CbGpPWpGaD
Etodolac—ALB—Metabolism—APOE—psoriasis	4.01e-06	0.000167	CbGpPWpGaD
Etodolac—ALB—Metabolism—PPARG—psoriasis	3.49e-06	0.000145	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—APOE—psoriasis	3.28e-06	0.000136	CbGpPWpGaD
Etodolac—PTGS2—Disease—STAT3—psoriasis	3.16e-06	0.000132	CbGpPWpGaD
Etodolac—CYP2C9—Metabolism—PPARG—psoriasis	2.86e-06	0.000119	CbGpPWpGaD
Etodolac—PTGS2—Disease—IL6—psoriasis	2.21e-06	9.19e-05	CbGpPWpGaD
